Dr. Oldach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Visterra, Inc.
275 2nd Avenue
Waltham, MA 02451Phone+1 617-401-2026- Is this information wrong?
Summary
- I am a Board Certified Infectious Disease Physician. After 18 years on faculty at the University of Maryland School of Medicine/Institute of Human Virology, I moved into drug development. First as Director in Clinical Development at Gilead (HCV/HBV), then as CMO at Cempra (antibiotics), currently as CMO at Visterra, an MIT-spinout monoclonal antibody developer (and now an Otsuka subsidiary). Visterra's focus is on developing better biologics for diseases of inflammation and immunity, focused principally on kidney disease, also with ongoing programs in selected infectious diseases.
Education & Training
Johns Hopkins UniversityFellowship, Infectious Disease, 1989 - 1992
Massachusetts General HospitalResidency, Internal Medicine, 1986 - 1989
University of Maryland School of MedicineClass of 1986
Certifications & Licensure
MD State Medical License 1989 - 2025- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV Start of enrollment: 2008 Apr 01
- Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia Start of enrollment: 2012 Dec 01
Publications & Presentations
PubMed
- 15 citationsSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgGMonoclonal Antibody, in Healthy Volunteers.Mohit Mathur, Jonathan Barratt, Yusuke Suzuki, Frank Engler, Marcela F Pasetti, Jill Yarbrough, Susan Sloan, David Oldach> ;Kidney International Reports. 2022 May 1
- 10 citationsClinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.Susan Sloan, Kristy J. Szretter, Bharathi Sundaresh, Kristin Narayan, Patrick F. Smith, David Skurnik, Sylvain Bedard, Jose M. Trevejo, David Oldach, Zachary Shriver> ;Antiviral Research. 2020 Mar 6
- 36 citationsSolithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): a randomised phase 3 non-inferiority trialMarcus Y Chen, Anna McNulty, Ann Avery, David M. Whiley, Sepehr N. Tabrizi, Dwight J. Hardy, Anita Das, Ashley Nenninger, Christopher K Fairley, Jane S Hocking, Catrio...> ;The Lancet. Infectious Diseases. 2019 Aug 1
- Join now to see all
Press Mentions
Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-Hospitalized Patients with Influenza ANovember 15th, 2018- Visterra Initiates Phase 1 Clinical Study of VIS649November 8th, 2018
- Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on Respiratory PathogensMarch 7th, 2018
- Join now to see all
Grant Support
- Needlestick HCV Exposure: Virologic &Immunologic EventsNational Institute Of Allergy And Infectious Diseases2000–2003
- Needlestick HCV Exposure--Virologic &Immunologic EventsNational Institute Of Allergy And Infectious Diseases1999
- Needlestick HCV Exposure Among Health Care WorkersNational Institute Of Allergy And Infectious Diseases1998–1999
- Murine Model For Hepatitis C Virus InvestigationsNational Institute Of Allergy And Infectious Diseases1996–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
